Search Results - "Kita, Aya"

Refine Results
  1. 1
  2. 2
  3. 3

    The proneural bHLH genes Mash1, Math3 and NeuroD are required for pituitary development by Ando, Mitsushige, Goto, Masanori, Hojo, Masato, Kita, Aya, Kitagawa, Masashi, Ohtsuka, Toshiyuki, Kageyama, Ryoichiro, Miyamoto, Susumu

    Published in Journal of molecular endocrinology (01-10-2018)
    “…Multiple signaling molecules and transcription factors are required for pituitary development. Activator-type bHLH genes Mash1, Math, NeuroD (Neurod) and…”
    Get full text
    Journal Article
  4. 4

    Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin by Okamoto, Kunio, Okamoto, Isamu, Hatashita, Erina, Kuwata, Kiyoko, Yamaguchi, Haruka, Kita, Aya, Yamanaka, Kentaro, Ono, Mayumi, Nakagawa, Kazuhiko

    Published in Molecular cancer therapeutics (01-01-2012)
    “…Loss of PTEN was recently shown to contribute to resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in EGFR…”
    Get full text
    Journal Article
  5. 5

    Hes1 and Hes5 are required for differentiation of pituicytes and formation of the neurohypophysis in pituitary development by Goto, Masanori, Hojo, Masato, Ando, Mitsushige, Kita, Aya, Kitagawa, Masashi, Ohtsuka, Toshiyuki, Kageyama, Ryoichiro, Miyamoto, Susumu

    Published in Brain research (02-11-2015)
    “…Abstract The pituitary gland is a critical endocrine organ regulating diverse physiological functions, including homeostasis, metabolism, reproduction, and…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Hes1 and Hes5 Control the Progenitor Pool, Intermediate Lobe Specification, and Posterior Lobe Formation in the Pituitary Development by Kita, Aya, Imayoshi, Itaru, Hojo, Masato, Kitagawa, Masashi, Kokubu, Hiroshi, Ohsawa, Ryosuke, Ohtsuka, Toshiyuki, Kageyama, Ryoichiro, Hashimoto, Nobuo

    Published in Molecular endocrinology (Baltimore, Md.) (01-06-2007)
    “…The pituitary gland is composed of two distinct entities: the adenohypophysis, including the anterior and intermediate lobes, and the neurohypophysis, known as…”
    Get full text
    Journal Article
  8. 8

    Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells by Kaneko, Naoki, Yamanaka, Kentaro, Kita, Aya, Tabata, Kenji, Akabane, Takafumi, Mori, Masamichi

    Published in Biological & pharmaceutical bulletin (01-12-2013)
    “…Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes, and effective treatment options are limited to cytotoxic agents,…”
    Get full text
    Journal Article
  9. 9

    Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation by Shakushiro, Kohsuke, Kawano, Hiroki, Nakata, Mari, Kita, Aya, Maeda, Atsushi, Watanabe, Shunsuke, Sako, Kazuhiro, Oku, Naoto

    Published in Pharmaceutical research (01-01-2015)
    “…Purpose Sepantronium bromide (YM155) is administered by 168-hour continuous infusions in clinical studies due to its time-dependent pharmacological efficacy…”
    Get full text
    Journal Article
  10. 10

    Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant by Kawano, Hiroki, Shakushiro, Kohsuke, Nakata, Mari, Kita, Aya, Maeda, Atsushi, Watanabe, Shunsuke, Sako, Kazuhiro, Oku, Naoto

    “…[Display omitted] •Liposomal YM155 greatly improved the level of YM155 circulating in the blood.•Liposomal YM155 showed unexpectedly high accumulation in the…”
    Get full text
    Journal Article
  11. 11

    Radiosynthesis, biodistribution and imaging of [11 C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model by Murakami, Yoshihiro, Matsuya, Takahiro, Kita, Aya, Yamanaka, Kentaro, Noda, Akihiro, Mitsuoka, Keisuke, Nakahara, Takahito, Miyoshi, Sosuke, Nishimura, Shintaro

    Published in Nuclear medicine and biology (01-02-2013)
    “…Abstract Introduction Sepantronium bromide (YM155) is an antitumor drug in development and is a first-in-class chemical entity, which is a survivin…”
    Get full text
    Journal Article
  12. 12

    Application of Spatial Domain Interferometry with the Capon Method to Transcranial Doppler Ultrasonography: a Simulation Study by Okumura, Shigeaki, Kita, Aya, Taki, Hirofumi, Nagatani, Yoshiki, Matsukawa, Mami, Sato, Toru

    Published in Advanced Biomedical Engineering (01-01-2015)
    “…Control of vasospasm is one of the most important problems in postoperative management after the occurrence of subarachnoid hemorrhage. Transcranial Doppler…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Synergistic Antitumor Activities of Sepantronium Bromide (YM155), a Survivin Suppressant, in Combination with Microtubule-Targeting Agents in Triple-Negative Breast Cancer Cells by Naoki Kaneko, Kentaro Yamanaka, Aya Kita, Kenji Tabata, Takafumi Akabane, Masamichi Mori

    Published in Biological and Pharmaceutical Bulletin (01-12-2013)
    “…Triple-negative breast cancer (TNBC) has a poor prognosis compared to other subtypes, and effective treatment options are limited to cytotoxic agents,…”
    Get full text
    Journal Article
  15. 15

    Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models by YAMANAKA, Kentaro, NAKAHARA, Takahito, YAMAUCHI, Tomohiro, KITA, Aya, TAKEUCHI, Masahiro, KIYONAGA, Fumiko, KANEKO, Naoki, SASAMATA, Masao

    Published in Clinical cancer research (15-08-2011)
    “…Aggressive cell growth and chemoresistance are notorious obstacles in melanoma therapy. Accumulating evidence suggests that survivin is preferentially…”
    Get full text
    Journal Article
  16. 16

    Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma by KANEKO, Naoki, MITSUOKA, Keisuke, AMINO, Nobuaki, YAMANAKA, Kentaro, KITA, Aya, MORI, Masamichi, MIYOSHI, Sosuke, KUROMITSU, Sadao

    Published in Clinical cancer research (01-04-2014)
    “…There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The purpose of this study was to evaluate…”
    Get full text
    Journal Article
  17. 17

    The proneural bHLH genes Mash1, Math3 and NeuroD are required for pituitary development by Ando, Mitsushige, Goto, Masanori, Hojo, Masato, Kita, Aya, Kitagawa, Masashi, Ohtsuka, Toshiyuki, Kageyama, Ryoichiro, Miyamoto, Susumu

    Published in Journal of molecular endocrinology (01-10-2018)
    “…Multiple signaling molecules and transcription factors are required for pituitary development. Activator-type bHLH genes Mash1, Math, NeuroD (Neurod) and…”
    Get full text
    Journal Article
  18. 18

    YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer by YAMANAKA, Kentaro, NAKATA, Mari, KANEKO, Naoki, FUSHIKI, Hiroshi, KITA, Aya, NAKAHARA, Takahito, KOUTOKU, Hiroshi, SASAMATA, Masao

    Published in International journal of oncology (01-09-2011)
    “…Metastatic triple negative breast cancer [TNBC, with negative expression of estrogen and progesterone receptors and no overexpression of HER2/neu (ErbB-2)]…”
    Get full text
    Journal Article
  19. 19

    Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155 by Mitsuoka, Keisuke, Kita, Aya, Murakami, Yoshihiro, Shirasuna, Kenna, Noda, Akihiro, Yamanaka, Kentaro, Kaneko, Naoki, Miyoshi, Sosuke

    Published in Nuclear medicine and biology (01-09-2018)
    “…Sepantronium bromide (YM155) is a survivin suppressant that induces apoptosis in tumor cells. Although YM155 induces tumor regression in various tumor types in…”
    Get full text
    Journal Article
  20. 20